Posts Tagged ‘Collaboration’

Genedata Screener Now Supports Streamlined Collaboration among Pharmas and CROs

Basel, Switzerland (PRWEB) May 12, 2015

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the Genedata Screener® platform supports data- and result-sharing with Contract Research Organizations (CROs). Genedata Screener provides a framework for systematic import, processing, and end-result propagation for all types of screening experiments, making it ideal for different collaboration models and partner ecosystems among pharmaceutical companies and CROs. As used by Roche, Genedata Screener is a comprehensive software solution supporting global operations, leveraged as a collaboration platform to help expedite drug discovery, reduce data analysis costs, and lower overhead for pharmaceutical R&D.

Web-based and cloud-compatible, Genedata Screener can be used as a data analysis and exchange platform. Installed at a CRO site, on-site or in the cloud, it enables a pharma’s CRO partner to easily exchange data with the pharma’s Screener instance. The system’s inherent business logic allows pharmas to maintain consistent workflows with their company-specific business rules for results regardless of the CRO doing the analysis.

Secure and Consistent Platform for Collaborative Research Lowers Total Cost of Ownership

Pharmaceutical companies – both large and small – are using collaborative research to help replenish therapeutic pipelines and advance innovation. Such collaborative research models provide access to specific technologies, streamline operations, lower costs, and accelerate drug discovery. Outsourcing screening and the corresponding data analysis to CROs is a valuable research model and business strategy for many leading pharmaceutical companies. This model increases flexibility for drug discovery and draws from a broader expertise for improved results.

Successful collaborative research with external partners requires all parties to have complete insight into the data produced by an experiment, the data analysis methods applied, and the rationale for decision making (e.g. specific artifact corrections or decisions on hit calling and compound progression). Having both in-house and external researchers using the same consistent methodology and standardized processing of results is critical for maintaining research integrity. Genedata Screener creates a framework for a successful collaboration paradigm as it provides a platform for sharing business rules and analysis methodologies as well as strict control of access, (re-)analysis, and modification permissions. Furthermore, all steps and modifications are tracked along the process, yielding a full audit trail across different functions and organizations.

Enabling CROs to collaborate with in-house scientists, Genedata Screener not only extends the lab bench, it also supports a variety of collaboration models (i.e. multi-sided and peer-to-peer). It helps pharmaceutical companies go beyond commodity screening with end-to-end data sharing and analysis, which can transfer raw data and results between two instances of Screener. Additional platform features include:

Automated Data Exchange for long-term collaboration spanning several projects. Results are synchronized through different Genedata Screener instances to easily collect and centralize project data and compound results.
IP Protection as the collaboration server is a Genedata Screener instance that requires precise definition of project access and information content per project.
Large Dataset Analysis – even in the cloud – to enable cost-effective and streamlined management and delivery of data analysis.

“Genedata Screener, used as a modern collaboration platform, continues to support evolving R&D needs without organizations making additional technology investments,” noted Dr. Othmar Pfannes, CEO of Genedata. “And, the beauty of this industry-leading low TCO is that it also accelerates the pace of novel drug discovery.”

About Genedata

Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. Follow Us on LinkedIn.

Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Related Small Business Press Releases

IIUSA Supports Inter-Agency Collaboration to Protect the Integrity of the EB-5 Program


Chicago, IL (PRWEB) October 03, 2013

The Association to Invest In the USA (IIUSA), the trade association representing more than 100 EB-5 Regional Centers, supports the recent action of the U.S. Securities and Exchange Commission (SEC) to stop a Regional Center in Texas from allegedly defrauding EB-5 investors. IIUSA also applauds the U.S. Citizenship and Immigration Services (USCIS) for its cooperation with the SEC in the matter.

“Proper oversight, transparency, compliance with – and enforcement of – all applicable securities, anti-fraud and immigration laws and regulations are essential to maintain the confidence of all industry stakeholders and ensure that the EB-5 program continues to bring capital and job creation to American communities,” said Peter D. Joseph, Executive Director of IIUSA.

“Our position is clear: efficient and effective enforcement of U.S. securities laws is as essential for the EB-5 program as it is for any investment vehicle,” said K. David Andersson, President of IIUSA.

The EB-5 Regional Center economic development program successfully spurs U.S. job creation and economic growth by attracting foreign direct investment in the United States. A comprehensive peer-reviewed economic study found that from 2010-2011, investments made through the EB-5 program contributed $ 2.2 billion to U.S. GDP and supported over 28,000 jobs at no cost to taxpayers. IIUSA’s members account for 95 percent of all capital raised through the EB-5 program.

IIUSA has a track record of working cooperatively with USCIS and other regulatory agencies to strengthen the program through effective enforcement of anti-fraud, securities and immigration law. For example, IIUSA recently filed an amicus brief supporting SEC action to stop a Regional Center and developer from making misleading claims about investment opportunities.

Other initiatives supported by IIUSA include:

An “Investor Alert” jointly issued by the SEC and USCIS that provides prospective EB-5 investors with information on conducting due diligence evaluations of EB-5 securities offerings.

Distribution of guidance published by FINRA for broker-dealers marketing EB-5 related securities.

Support for several important reforms included in the comprehensive immigration reform legislation that recently passed the full Senate that would strengthen law enforcement and national security protections.

“Investments made through EB-5 Regional Centers provide a new, vital source of funding for local economic development projects, often in partnership with local governments and economic development agencies. These successful projects are revitalizing communities across the country, creating and supporting jobs, infrastructure and services,” noted Joseph. “Protecting the integrity of the program is critical to continue bringing jobs and economic benefits to cities and towns across the country.”


Founded in 2005, the Association to Invest In the USA (IIUSA) is the national not-for-profit industry trade association for the EB-5 Regional Center Program, representing well over 100 Regional Center members that account for over 95 percent of the capital flowing through the Program. IIUSA represents the industry in government and public affairs, telling the story of how the EB-5 Program has become a fundamental part of U.S. economic development policy – with operations covering advocacy, industry development, and education. An essential part of IIUSA’s mission is to stimulate economic development and job growth through continued success of the program as well as advance and maintain industry standards and best practices.

Follow us on:

Contact's Google Plus

Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

World Leaders in Alzheimer’s Innovation to Discuss Progress, Collaboration at DIA Annual Meeting

Horsham, Pa. (PRWEB) June 17, 2013

Without treatment, experts say, the number of Alzheimer’s disease patients worldwide is expected to almost double by 2025 to 34 million people—a startling realization that’s driving global forces to join together to advance research for the debilitating disease before it’s too late.

A number of innovative initiatives hold hope for a promising future in understanding Alzheimer’s, including new ways to implement genome sequencing in research, focus on much-needed support for caregivers and look for novel methods to improve clinical trials. These breakthrough efforts will be discussed on June 26 by U.S. leaders in Alzheimer’s research and regulation in three Advancing Alzheimer’s Innovation sessions at the DIA 2013 49th Annual Meeting at the Boston Convention & Exhibition Center.

Scientists are now focusing on the interaction of gender, genetic risk factors and biological markers of the disease. Harvard Medical School professors Dr. Rudy Tanzi, director of the Genetics and Aging Research Unit of the MassGeneral Institute for Neurodegenerative Disease and recently profiled by The Boston Globe and cited as a “rock star of science” by GQ, and Dr. Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, will join a panel of experts discussing collaboration to support research at Advancing Alzheimer’s Innovation: A Call to Action.

Tanzi, leader of the Whole Genome Sequencing Project, aims to propel research to identify the genetic risk for Alzheimer’s disease—a vital step in discovering a therapy.

“We are taking advantage of cutting-edge technology to discover exactly how our genes determine susceptibility to Alzheimer’s disease,” Tanzi said. “This panel will discuss how this key knowledge will pioneer novel drug discovery efforts and pave the future of Alzheimer’s research.”

Sperling is the principal investigator for the first-ever clinical trial aimed at older people who are at genetic risk of developing Alzheimer’s, but who have yet to show symptoms. Sperling will discuss the new era of prevention trials and the importance of studying the role gender may play in developing the disease. The three-year-long clinical trial, launching in November, will be made up of 1,000 older individuals and is funded jointly by the National Institutes of Health and Eli Lilly.

“It is critical to understand the interaction of risk factors and biological markers of disease pathology as we move forward with the trial,” Sperling said.

Adding to the discussion about innovative approaches to treating Alzheimer’s, Dr. Nicholas Kozauer, clinical lead for the Food and Drug Administration’s Division of Neurology Products, will address the need for a regulatory framework for pre-dementia clinical trials. In March, Kozauer published a compelling piece in the New England Journal of Medicine on the need for innovative approaches in trial design and selection as the drug-development community turns its sights on the early stages of the disease.

The session is chaired by Meryl Comer, president of the Geoffrey Beene Foundation Alzheimer’s Initiative, which just launched a $ 100,000 Global NeuroDiscovery Challenge to look at gender-based differences in Alzheimer’s. George Vradenburg, chairman of USAgainstAlzheimer’s, will discuss plans to use the G-8 to develop an international approach to address Alzheimer’s and dementia.

Below are the two other June 26 sessions focused on Alzheimer’s treatment and care:

Advancing Alzheimer’s Innovation: Patient Advocacy, Caregiver Support and Health Care System Impact at 1:45 p.m.

New initiatives are responding to the growing stress on caregivers and the need to help individuals remain independent for as long as possible. Robert Feeney, senior director of evidence-based reimbursement for Sanofi, will lead a panel of experts discussing the initiatives that prepare society for the proper care of Alzheimer’s patients and caregivers. The forum will address best practices in delivery of care, whether in institutions or at home.

Advancing Alzheimer’s Innovation: Clinical Development Successes and Challenges at 4 p.m.

Only about 8 percent of drugs that treat diseases—including Alzheimer’s—affecting the central nervous system enter clinical trials and the U.S. market. Innovative approaches to clinical design are needed to advance the success rate of drugs that treat Alzheimer’s. Sperling, discussing the current landscape of Alzheimer’s clinical trials and lessons learned from past trials, will join executives from Eisai Inc., and Merck & Co., to address the challenges encountered in clinical development and recommendations in design to improve the success of clinical trials.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.



Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Related Marketing & Sales Press Releases